15,783 Shares in AstraZeneca PLC $AZNCF Acquired by Founders Financial Securities LLC

Founders Financial Securities LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,783 shares of the company’s stock, valued at approximately $3,235,000.

A number of other institutional investors have also recently added to or reduced their stakes in AZNCF. Vaughan David Investments LLC IL acquired a new stake in AstraZeneca in the fourth quarter worth $88,367,000. Captrust Financial Advisors bought a new stake in AstraZeneca in the fourth quarter valued at $24,965,000. Azimuth Capital Investment Management LLC bought a new stake in AstraZeneca in the fourth quarter valued at $20,440,000. L & S Advisors Inc acquired a new position in shares of AstraZeneca during the fourth quarter valued at $14,863,000. Finally, Hendley & Co. Inc. acquired a new position in shares of AstraZeneca during the fourth quarter valued at $11,373,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AstraZeneca stock opened at $187.10 on Friday. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00. The company has a 50-day simple moving average of $187.10 and a 200-day simple moving average of $186.01.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.